Short answer

Bio-rad Laboratories Inc (BIO) filed its fiscal 2014 10-K annual report with the SEC on Mar 2, 2015.

Top risk flagged: FCPA settlement: DOJ and SEC NPA, effective November 3, 2014, requiring penalties, disgorgement, interest and two-year compliance obligations

Bio-rad Laboratories Inc FY2014 10-K analysis

AI summary of each section, grounded in the filing text

Core model: Global supplier of life science research tools and clinical diagnostics systems, products, and consumables
Two segments emphasized: Life Science, 33% of sales; Clinical Diagnostics, 66%, targeting higher-margin, higher-growth niches
International positioning: 68% of sales outside the United States, with direct distribution in over 35 countries
R&D investment reached $220.3 million in 2014, up from $211.0 million in 2013
Distinctive recurring diagnostics model: installed systems drive continuing test-kit and consumables revenue

Revenue $2.18B, up 2.0% YoY from $2.13B, with currency-neutral growth of 3.3%
Clinical Diagnostics largest segment, $1.43B sales, up 1.7%; Life Science strongest growth, $728.3M, up 2.6%
Gross margin 54.2% vs 55.3%; net income margin 4.1% vs 3.6%; effective tax rate 32% vs 31%
Operating cash flow $273.3M; capex $121.0M; GnuBIO acquisition consideration $50.4M
Cash, equivalents and short-term investments $697.6M; FCPA settlement $55.1M; ERP implementation expected to exceed $300M as key risk

FCPA settlement: DOJ and SEC NPA, effective November 3, 2014, requiring penalties, disgorgement, interest and two-year compliance obligations
International exposure: foreign subsidiaries generated 68% of 2014 net sales, with $45.4 million receivables in Spain, Italy, Greece and Portugal
ERP vulnerability: first Clinical Diagnostics deployment disrupted invoicing and increased accounts receivable
Diagnostics disruption: molecular diagnostics and point-of-care testing trends threaten product relevance
Debt burden: $436.0 million outstanding indebtedness plus $200.0 million revolving facility capacity

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.